CamGFR v2: a new model for estimating the glomerular filtration rate from standardized or non-standardized creatinine in patients with cancer
AuthorsWilliams, E. H.
Flint, T. R.
Connell, C. M.
Bird, N. J.
Weaver, Jamie M
Whitley, C. T.
Bookman, M. A.
Lynch, A. G.
Meyer, H. V.
AffiliationCancer Research UK Cambridge Institute.
MetadataShow full item record
AbstractPurpose: Management of patients with cancer, specifically carboplatin dosing, requires accurate knowledge of glomerular filtration rate (GFR). Direct measurement of GFR is resource-limited. Available models for estimated GFR (eGFR) are optimized for patients without cancer and either isotope dilution mass spectrometry (IDMS)- or non-IDMS-standardized creatinine measurements. We present an eGFR model for patients with cancer compatible with both creatinine measurement methods. Methods: GFR measurements, biometrics, and IDMS- or non-IDMS-standardized creatinine values were collected for adult patients from three cancer centers. Using statistical modelling, an IDMS- and non-IDMS creatinine compatible eGFR model (CamGFR v2) was developed. Its performance was compared to that of the existing models CKD-EPI, MDRD, FAS, Lund-Malmo Revised and CamGFR v1 using statistics for bias, precision, accuracy, and clinical robustness. Results: 3,083 IDMS- and 4,612 non-IDMS-standardized creatinine measurements were obtained from 7,240 patients. IDMS-standardized creatinine values were lower than non-IDMS-standardized values in within-centercomparisons (13.8% lower in Cambridge, p<0.0001; 19.3% lower in Manchester, p <0.0001), and more consistent between centers. CamGFR v2 was the most accurate (root-mean-squared error for IDMS = 14.97ml/min[95% CI 13.84,16.13]; non-IDMS = 15.74ml/min[14.86,16.63]), most clinically robust (proportion with >20% error of calculated carboplatin dose for IDMS = 0.12[0.09, 0.14]; non-IDMS = 0.17[0.15, 0.2]) and least biased (median residual for IDMS = 0.73ml/min[-0.68,2.2]; non-IDMS = -0.43ml/min[-1.48,0.91]) eGFR model, particularly when eGFR was larger than 60ml/min. Conclusions: CamGFR v2 can utilize IDMS- and non-IDMS-standardized creatinine measurements and outperforms previous models. CamGFR v2 should be examined prospectively as a practice-changing standard of care for eGFR-based carboplatin dosing.
CitationWilliams EH, Flint TR, Connell CM, Giglio D, Lee H, Ha T, et al. CamGFR v2: a new model for estimating the glomerular filtration rate from standardized or non-standardized creatinine in patients with cancer. Clin Cancer Res. 2020.
JournalClinical Cancer Research
- Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan.
- Authors: Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S
- Issue date: 2007 Dec
- Multicenter Validation of the CamGFR Model for Estimated Glomerular Filtration Rate.
- Authors: Williams EH, Connell CM, Weaver JMJ, Beh I, Potts H, Whitley CT, Bird N, Al-Sayed T, Monaghan PJ, Fehr M, Cathomas R, Bertelli G, Quinton A, Lewis P, Shamash J, Wilson P, Dooley M, Poole S, Mark PB, Bookman MA, Earl H, Jodrell D, Tavaré S, Lynch AG, Janowitz T
- Issue date: 2019 Dec
- Prediction of relative glomerular filtration rate in adults: new improved equations based on Swedish Caucasians and standardized plasma-creatinine assays.
- Authors: Björk J, Bäck SE, Sterner G, Carlson J, Lindstrom V, Bakoush O, Simonsson P, Grubb A, Nyman U
- Issue date: 2007
- Enzymatic creatinine assays allow estimation of glomerular filtration rate in stages 1 and 2 chronic kidney disease using CKD-EPI equation.
- Authors: Kuster N, Cristol JP, Cavalier E, Bargnoux AS, Halimi JM, Froissart M, Piéroni L, Delanaye P, Société Française de Biologie Clinique (SFBC).
- Issue date: 2014 Jan 20
- Calibration and precision of serum creatinine and plasma cystatin C measurement: impact on the estimation of glomerular filtration rate.
- Authors: Delanaye P, Cavalier E, Cristol JP, Delanghe JR
- Issue date: 2014 Oct